Retatrutide (GLP-3)

Pharmaceutical-grade research peptide, lyophilized for stability. Each batch is independently tested and COA-verified with ≥99% purity by HPLC analysis. Intended exclusively for research purposes.

Retatrutide is studied as an experimental triple hormone receptor agonist targeting GLP-1, GIP and glucagon receptors simultaneously. Researchers examine obesity, body weight, glucose homeostasis, energy expenditure, lipids, liver fat and broader cardiometabolic markers. Phase 2 literature reports substantial weight reduction in adults with obesity. The scientific interest centres on whether combined incretin and glucagon receptor signalling can produce greater metabolic effects than single or dual agonists. This compound remains in clinical development.

For laboratory research use only. This information describes areas of scientific investigation and does not constitute medical advice, dosing guidance or therapeutic claims.